quadrivalent human papillomavirus vaccine — Competitive Intelligence Brief

quadrivalent human papillomavirus vaccine (quadrivalent human papillomavirus vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Oncology / Immunology.

marketed vaccine Human papillomavirus types 6, 11, 16, 18 Oncology / Immunology Biologic

Target snapshot

quadrivalent human papillomavirus vaccine (quadrivalent human papillomavirus vaccine) — University of Pittsburgh. The vaccine stimulates the immune system to produce antibodies against four types of human papillomavirus (HPV types 6, 11, 16, and 18) to prevent infection and associated diseases.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
quadrivalent human papillomavirus vaccine TARGET	quadrivalent human papillomavirus vaccine	University of Pittsburgh	marketed	vaccine	Human papillomavirus types 6, 11, 16, 18
Gardasil 9 rescue dose	Gardasil 9 rescue dose	Boston Medical Center	marketed	Recombinant HPV vaccine	Human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, 58
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
MCV-A vaccine	MCV-A vaccine	International Vaccine Institute	marketed	Meningococcal conjugate vaccine	Meningococcal serogroup A capsular polysaccharide
Rotavirus Vaccine (ROTARIX)	Rotavirus Vaccine (ROTARIX)	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	Live attenuated vaccine
Aleph influenza vaccine	Aleph influenza vaccine	Beijing Center for Disease Control and Prevention	marketed	vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

1. Pfizer · 20 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
3. GlaxoSmithKline · 12 drugs in this class
4. Merck Sharp & Dohme LLC · 12 drugs in this class
5. Centers for Disease Control and Prevention · 9 drugs in this class
6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
10. Sinovac Biotech Co., Ltd · 4 drugs in this class